PDA 731 Practical Application of Risk-Based GMP and Quality Principles to Clinical Development of ATMPs
Registration Options
Individual Registration
Group Registration
There has been a surge in clinical development of Advanced Therapy Medicinal Products (ATMPs), both in the EU and US. Many start-up companies, and now even large biopharmaceutical companies, are planning or have already entered into manufacturing these genetically engineered viruses and/or human cell products for clinical studies.
While the ground rules for Good Manufacturing Practices (GMPs) and quality of recombinant protein and monoclonal antibody manufacturing and control are well established, for ATMPs these are still under development. ATMP manufacturing and control presents unique GMP and quality challenges, such as the heightened concern about the safety/variability of the starting materials, the quality of the raw materials added during processing, the need to protect against adventitious agent contamination throughout the entire manufacturing cycle, the limited analytical methods available to characterize these ATMPs, and the reality that the administered clinical medicinal product is a complex living organism. In addition, the expedited pace of clinical studies for these ATMPs places enormous pressure on the need to also rapidly develop and enhance the manufacturing process control systems.
Patients in these clinical development programs need to be protected by common sense GMPs and quality principles. The available EMA/FDA regulatory authority guidance documents for ATMPs will be thoroughly examined. In addition, the core, risk-based principles presented in PDA’s 2018 Technical Report No. 81: Cell-Based Therapy Control Strategy, will be discussed.
- Identify the GMP and quality similarities and differences between protein medicinal products and ATMPs
- Explain how to apply a risk-based approach to the manufacturing and quality control of ATMPs
- Explain and justify the importance and underlying GMP and quality principles for ATMPs during clinical stages of development
Contact
Program Inquiries
Training Course Inquiries
Registration Customer Care
Standard Pricing
Standard Member Price
$599GovernmentMember Only
$599
Health AuthorityMember Only
$599
Early Career ProfessionalMember Only
$599
StudentMember Only
$599
AcademicMember Only
$599
Non-Member
$599
Day 1
Welcome and Introductions (30 min)
Overview of the ATMP Landscape (90 min)
- Defining the critical terminology: CGTP, ATMP, CAT, OTAT, RMAT, etc.
- How the diversity of ATMPs challenge the application of GMP and quality
Break (15 min)
ATMP GMP and Quality Risk Consequences (90 min)
- Major differences between gene/cell-based medicines and protein-based medicines
- Necessity of a risk-based approach
Break (60 min)
Regulatory Authority Expectations During Clinical Development (90 min)
- FDA guidances and risk-based considerations for ATMPs
- EMA guidelines and comparison to FDA
Break (15 min)
Industry Practice in Applying Risk-Based Considerations to ATMPs (90 min)
- PDA Technical Report No. 81
- Lessons learned from industry practice
Become a Sponsor
Interested in becoming a sponsor? Learn about opportunities and benefits.
Request InformationBecome an Exhibitor
Interested in becoming an exhibitor? Learn about opportunities and benefits.
Request InformationPLEASE READ PDA is not affiliated or contracted with any outside hotel contracting company. If someone other than PDA or the PDA chosen hotel contacts you suggesting that they represent any PDA event, they do not. It is PDA's recommendation that you book your hotel directly through the official PDA chosen hotel that is listed on our web site.